Koji Takeda1, Serge Kobsa1, Yuji Kaku1, Hiroo Takayama1. 1. Division of Cardiac, Thoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY.
Koji Takeda, MD, PhD, Serge Kobsa, MD, Yuji Kaku, MD, and Hiroo Takayama, MD, PhDNo cannulation strategy for VA-ECMO is perfect. Surgeons should make individualized decisions on the appropriate arterial cannulation site and revise to an alternate cannulation site when required.See Article page 62.While arterial cannulation strategy is paramount to success in the management of peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO), there is wide variability in practice due to a lack of established consensus or guidelines. Peripheral cannulation in femoral or axillary artery is generally preferred over central cannulation in ascending aorta. In this issue of the Journal, Ohira and colleagues reported their experience with axillary cannulation for VA-ECMO. Including 218 patients receiving axillary cannulation, the study is one of the largest reports of axillary cannulation for VA-ECMO. While this cohort was compared with 153 patients receiving femoral cannulation, the comparative analysis is largely descriptive. Nonetheless, it paints a landscape of the peripheral arterial cannulation strategy and its outcomes at the authors' institution.Compared with femoral cannulation, axillary cannulation provides antegrade systemic circulation, diminishes upper-body hypoxia related to the mixing cloud, and minimizes aortic root thrombus formation. When combined with internal jugular vein drainage, it can allow ambulatory rehabilitation on VA-ECMO. Axillary cannulation, however, presents a number of challenges. First and most of all, it requires time and expertise, and thus the critical condition of the patient may not allow its application. Hyperperfusion syndrome, only 5 cases (2.3%) reported by Ohira and colleagues, could be seen up to quarter of all axillary cannulations. Although the bleeding complication rate was not different between cannulation sites, Ohira and colleagues reported a 15.1% bleeding rate with axillary cannulation. Anastomotic bleeding or oozing through the graft is frequently seen and is extremely difficult to control once VA-ECMO flow is established. Several tips may help avoid these complications: (1) the graft may be beveled to allow more centrally directed blood flow; (2) distal flow control by axillary artery banding or direct cannulation with distal perfusion can be effective; and (3) use of lower pump flow will reduce pressure on the anastomosis while it may inadvertently compromise end-organ perfusion. Regarding the third point, the authors mentioned in the article that “pump flow of .5-2.2 L/min/m2 generally provide adequate support, while reducing line pressure”; however, data on organ perfusion were not shown.Femoral vessels are our first choice., Leg ischemia, a primary concern with femoral cannulation, can be mitigated through placing distal perfusion catheters, using a small arterial cannula, and monitoring tissue oxygenation in the legs. Wound complications, another concern with femoral cannulation, might be reduced with percutaneous decannulation techniques using a percutaneous closing device.,,Ohira and colleagues showed the overall cerebrovascular accident rate did not differ between cannulation sites. This observation is consistent with the unpublished data of our program; however, others reported greater stroke rate with femoral cannulation than axillary. We have so many other issues to discuss, like left ventricular distension, acute renal injury, and anticoagulation strategy, for which this margin is too narrow to contain.Neither cannulation strategy is perfect. For the time being, we will continue making individualized decisions regarding the most appropriate arterial cannulation site and learn to revise to an alternate site when required. Sometimes sites could be combined.
Authors: Themistokles Chamogeorgakis; Brian Lima; Alexis E Shafii; Dave Nagpal; Julie A Pokersnik; Jose L Navia; David Mason; Gonzalo V Gonzalez-Stawinski Journal: J Thorac Cardiovasc Surg Date: 2012-09-20 Impact factor: 5.209
Authors: Scott C DeRoo; Hiroo Takayama; Samantha Nemeth; A Reshad Garan; Paul Kurlansky; Susan Restaino; Paolo Colombo; Maryjane Farr; Yoshifumi Naka; Koji Takeda Journal: J Thorac Cardiovasc Surg Date: 2019-02-28 Impact factor: 5.209
Authors: Hiroo Takayama; Elissa Landes; Lauren Truby; Kevin Fujita; Ajay J Kirtane; Linda Mongero; Melana Yuzefpolskaya; Paolo C Colombo; Ulrich P Jorde; Paul A Kurlansky; Koji Takeda; Yoshifumi Naka Journal: J Thorac Cardiovasc Surg Date: 2015-02-07 Impact factor: 5.209
Authors: Michael Salna; Hiroo Takayama; Arthur R Garan; Paul Kurlansky; Maryjane A Farr; Paolo C Colombo; Thomas Imahiyerobo; Nicholas Morrissey; Yoshifumi Naka; Koji Takeda Journal: J Vasc Surg Date: 2017-08-16 Impact factor: 4.268
Authors: Mohammed F Hassan; Mark Lawrence; Daniel Lee; Jorge Velazco; Christopher Martin; Ramachandra Reddy Journal: J Card Surg Date: 2019-11-05 Impact factor: 1.620
Authors: Koji Takeda; Arthur R Garan; Masahiko Ando; Jiho Han; Veli K Topkara; Paul Kurlansky; Melana Yuzefpolskaya; Maryjane A Farr; Paolo C Colombo; Yoshifumi Naka; Hiroo Takayama Journal: Eur J Cardiothorac Surg Date: 2017-12-01 Impact factor: 4.191
Authors: Enzo Lüsebrink; Christopher Stremmel; Konstantin Stark; Tobias Petzold; Ralph Hein-Rothweiler; Clemens Scherer; Dominik Schüttler; Steffen Massberg; Martin Orban Journal: Crit Care Explor Date: 2019-06-26